Brokerages Expect Xylem Inc. (NYSE:XYL) Will Post Quarterly Sales of $1.25 Billion

Wall Street brokerages expect that Xylem Inc. (NYSE:XYLGet Rating) will report $1.25 billion in sales for the current quarter, Zacks reports. Five analysts have provided estimates for Xylem’s earnings, with estimates ranging from $1.23 billion to $1.33 billion. Xylem posted sales of $1.26 billion in the same quarter last year, which suggests a negative year-over-year growth rate of 0.8%. The firm is expected to issue its next quarterly earnings report before the market opens on Monday, January 1st.

According to Zacks, analysts expect that Xylem will report full year sales of $5.29 billion for the current fiscal year, with estimates ranging from $5.26 billion to $5.33 billion. For the next fiscal year, analysts forecast that the business will report sales of $5.70 billion, with estimates ranging from $5.66 billion to $5.80 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that follow Xylem.

Xylem (NYSE:XYLGet Rating) last announced its quarterly earnings data on Thursday, February 3rd. The industrial products company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.01. The business had revenue of $1.32 billion for the quarter, compared to analyst estimates of $1.31 billion. Xylem had a return on equity of 14.67% and a net margin of 8.22%. The company’s revenue was down 3.6% on a year-over-year basis. During the same period in the prior year, the company earned $0.81 earnings per share.

A number of research analysts have recently weighed in on the company. TheStreet lowered Xylem from a “b” rating to a “c+” rating in a report on Monday, February 7th. Raymond James upgraded Xylem from an “underperform” rating to a “market perform” rating in a research note on Tuesday, April 5th. Morgan Stanley lowered their target price on Xylem from $120.00 to $110.00 and set an “overweight” rating on the stock in a research note on Monday, April 18th. Credit Suisse Group lowered their target price on Xylem from $111.00 to $98.00 and set an “underperform” rating on the stock in a research note on Friday, February 4th. Finally, Zacks Investment Research upgraded Xylem from a “strong sell” rating to a “hold” rating and set a $92.00 target price on the stock in a research note on Wednesday, April 6th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $114.45.

In other news, SVP Colin R. Sabol sold 4,233 shares of the firm’s stock in a transaction that occurred on Monday, April 18th. The stock was sold at an average price of $83.05, for a total value of $351,550.65. Following the transaction, the senior vice president now owns 27,373 shares in the company, valued at $2,273,327.65. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.89% of the company’s stock.

Several large investors have recently bought and sold shares of XYL. Norges Bank acquired a new stake in shares of Xylem in the fourth quarter valued at approximately $207,124,000. BlackRock Inc. increased its holdings in shares of Xylem by 5.0% in the fourth quarter. BlackRock Inc. now owns 18,052,578 shares of the industrial products company’s stock valued at $2,164,867,000 after purchasing an additional 852,446 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in shares of Xylem by 80.3% in the fourth quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 721,999 shares of the industrial products company’s stock valued at $86,582,000 after purchasing an additional 321,549 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Xylem in the fourth quarter valued at approximately $33,575,000. Finally, Baillie Gifford & Co. increased its holdings in shares of Xylem by 11.2% in the fourth quarter. Baillie Gifford & Co. now owns 2,519,654 shares of the industrial products company’s stock valued at $302,157,000 after purchasing an additional 254,493 shares during the last quarter. 83.99% of the stock is owned by hedge funds and other institutional investors.

Shares of XYL stock opened at $84.67 on Friday. The stock’s 50-day simple moving average is $86.96 and its 200-day simple moving average is $107.38. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.77 and a current ratio of 2.27. The firm has a market capitalization of $15.25 billion, a PE ratio of 36.03, a P/E/G ratio of 2.72 and a beta of 1.11. Xylem has a fifty-two week low of $82.03 and a fifty-two week high of $138.78.

The company also recently announced a quarterly dividend, which was paid on Thursday, March 17th. Stockholders of record on Thursday, February 17th were given a $0.30 dividend. This represents a $1.20 annualized dividend and a dividend yield of 1.42%. The ex-dividend date of this dividend was Wednesday, February 16th. This is an increase from Xylem’s previous quarterly dividend of $0.28. Xylem’s dividend payout ratio (DPR) is 51.06%.

Xylem Company Profile (Get Rating)

Xylem Inc, together with its subsidiaries, engages in the design, manufacture, and servicing of engineered products and solutions for the water and wastewater applications in the United States, Europe, the Asia Pacific, and internationally. It operates through three segments: Water Infrastructure, Applied Water, and Measurement & Control Solutions.

Featured Stories

Get a free copy of the Zacks research report on Xylem (XYL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xylem (NYSE:XYL)

Receive News & Ratings for Xylem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xylem and related companies with MarketBeat.com's FREE daily email newsletter.